1.45Open1.45Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover202.54%IV3.95%PremiumJul 19, 2024Expiry Date1.30Intrinsic Value100Multiplier19DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.8714Delta0.1178Gamma2.62Leverage Ratio-0.0099Theta0.0010Rho2.28Eff Leverage0.0018Vega
Rani Therapeutics Stock Discussion
NEWS
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
Rani Therapeutics, a clinical-stage biotherapeutics company, will present clinical and preclinical data on their oral delivery platform, the RaniPill® capsule, at Digestive Disease Week 2024. The data will focus on the oral delivery of an Ustekinumab biosimilar, showcasing high bioavailability in health...
NEWS
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
Rani Therapeutics reported positive topline results from a Phase 1 study for RT-111, an oral anti-Interleukin 12/23 antibody, and plans to initiate a Phase 2 clinical trial for RT-102 for osteoporosis treatment in 2024. The company's RaniPill HC is set for potential Phase 1 trials later in 2024. Financially, Rani Therapeutics had $39.6 million in cash, cash equivalents, and...
In reaction to earnings/guidance:
• $Payoneer Global(PAYO.US)$ +19.4%, $Toast(TOST.US)$ +13.1%, $PDF Solutions(PDFS.US)$ +7.7%, $Wheels Up Experience(UP.US)$ +7.1%, $LegalZoom(LZ.US)$ +6.5%, $Joby Aviation(JOBY.US)$ +3.6%, $indie Semiconductor(INDI.US)$ +2.9%, $Rocket Lab(RKLB.US)$ +2.4%, $Rivian Automotive(RIVN.US)$ +1.2%
Other news:
• $WeTrade Group(WETG.US)$ +47.8%(announces $50 million sales of monkeypox virus test kits to Par...
No comment yet